IN8bio, Inc.

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical

Current securities

1. S-8 filingAug 7, 2026
2. 10-Q filingAug 6, 2026
3. Results of Operations and Financial ConditionAug 6, 2026
4. Entry into a Material Definitive Agreement · Termination of a Material Definitive AgreementJun 1, 2026
5. 424B5 filingJun 1, 2026